Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand
Kai Yang, Shunyao Li, Tianqi Wang, Xueming Yan, He Qian, Ruonan Ning, Xing Yue Xu, Wei Yao 等 12 位
Shanghai Jiao Tong University Ruijin Hospital Chinese Academy of Sciences Shanghai Institute of Materia Medica
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Receptor activator of nuclear factor-κB (RANK) and its ligand, RANKL, play pivotal roles in bone remodeling. The monoclonal antibody denosumab successfully inhibited the maturation of osteoclasts (OCs) by binding to RANKL in the clinic. We continued our efforts to develop small-molecule inhibitors of RANKL. In this work, 41 β-carboline derivatives were synthesized based on previously synthesized compound Y1599 to improve its drug-like properties. Compound Y1693 was identified as a potent RANKL inhibitor that improved absorption–distribution–metabolism–excretion properties and effectively prevented RANKL-induced osteoclastogenesis and bone resorption. Furthermore, Y1693 also suppressed the expression of OC marker genes. Moreover, Y1693 demonstrated good tolerability and efficacy in an orally administered mouse model of osteoporosis as well as the ability to rescue alveolar bone loss in vivo caused by periodontal disease. Collectively, the above findings may provide a valuable direction for the development of novel antiresorptive therapies that target RANKL.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Bone Metabolism and Diseases
Computational Drug Discovery Methods · Bone health and treatments
参考文献 43
此处列出前 3 条
引用本文 17
按被引量排序,此处列出前 3 条